Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

被引：4
|
作者：
Zelenetz, Andrew D. [1 ]
Jurczak, Wojciech [2 ]
Ribrag, Vincent [3 ]
Linton, Kim M. [4 ,5 ]
Collins, Graham P. [6 ]
Bishton, Mark [7 ]
Lopez Jimenez, Javier [8 ]
Dholaria, Bhagirathbhai [9 ]
Mengarelli, Andrea [10 ]
Phillips, Tycel J. [11 ]
Sungala, Nagendra Prasad [12 ]
Chan, Henry [13 ]
Musuraca, Gerardo [14 ]
Sheehy, Oonagh [15 ]
Yan, Junyi [16 ]
Xu, Weiming [16 ]
Azoulay, Michel [17 ]
Zinzani, Pier Luigi [18 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland
[3] Gustave Roussy Canc Campus, Villejuif, France
[4] Christie NHS Fdn Trust, Manchester, Lancs, England
[5] Manchester Canc Res Ctr, Manchester, Lancs, England
[6] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England
[7] Nottingham Univ Hosp, Nottingham, England
[8] Hosp Univ Ramon y Cajal, Hematol Serv, Madrid, Spain
[9] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN USA
[10] Regina Elena Inst Canc Res, Rome, Italy
[11] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
[12] Liverpool Hosp, Dept Haematol, Sydney, NSW, Australia
[13] North Shore Hosp, Auckland, New Zealand
[14] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[15] Belfast HSC Trust, Belfast, Antrim, North Ireland
[16] MEI Pharma Inc, San Diego, CA USA
[17] Kyowa Kirin Co, Princeton, NJ USA
[18] Univ Bologna, Inst Hematol Seregnoli, Bologna, Italy
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165409
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3595 / 3597
页数：3
相关论文
共 50 条
  • [31] Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory ( R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.
    Ghosh, Nilanjan
    Salles, Gilles A.
    Lossos, Izidore S.
    Palomba, Maria Lia
    Mehta, Amitkumar
    Casasnovas, Olivier
    Stevens, Don A.
    Katakam, Sudhakar
    Knapp, Andrea
    Nielsen, Tina
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
    Falchi, Lorenzo
    Leppa, Sirpa
    Wahlin, Bjorn E.
    Nijland, Marcel
    Christensen, Jacob Haaber
    De Vos, Sven
    Holte, Harald
    Linton, Kim M.
    Abbas, Aqeel
    Wang, Liwei
    Dinh, Minh
    Elliott, Brian
    Belada, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
    Schuster, Stephen J.
    Fowler, Nathan Hale
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, P. Joy
    Perez-Simon, Jose Antonio
    Chen, Andy I.
    Nastoupil, Loretta J.
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers E. M.
    McGuirk, Joseph P.
    Petzer, Andreas L.
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Zia, Aiesha
    Awasthi, Rakesh
    Paule, Ines
    Germano, Davide
    Ramos, Roberto
    Hsu, Pei
    Thieblemont, Catherine
    Dreyling, Martin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S495 - S496
  • [34] EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
    Falchi, Lorenzo
    Morschhauser, Franck
    Linton, Kim
    Huang, Huiqiang
    Galderisi, Faith
    Quadri, Syed
    Zeng, Lingmin
    Hoehn, Daniela
    Seymour, John F.
    BLOOD, 2023, 142
  • [35] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
    Lynch, Ryan C.
    Paneesha, Shankara
    Avigdor, Abraham
    McKinney, Matthew S.
    Wahlin, Bjorn E.
    Hrom, John S.
    Belada, David
    Canales, Miguel
    Cunningham, David
    Devizzi, Liliana
    Morley, Nicholas
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Trneny, Marek
    BLOOD, 2020, 136
  • [36] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
    Lynch, Ryan C.
    Paneesha, Shankara
    Avigdor, Abraham
    McKinney, Matthew S.
    Wahlin, Bjorn E.
    Hrom, John S.
    Belada, David
    Canales, Miguel
    Cunningham, David
    Devizzi, Liliana
    Morley, Nicholas
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Trneny, Marek
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
  • [37] Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
    Noriko Fukuhara
    Koji Kato
    Hideki Goto
    Tajima Takeshi
    Mayu Kawaguchi
    Kota Tokushige
    Koichi Akashi
    Takanori Teshima
    Hideo Harigae
    Stephen J. Schuster
    Catherine Thieblemont
    Martin Dreyling
    Nathan Fowler
    International Journal of Hematology, 2023, 117 : 251 - 259
  • [38] Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
    Fukuhara, Noriko
    Kato, Koji
    Goto, Hideki
    Takeshi, Tajima
    Kawaguchi, Mayu
    Tokushige, Kota
    Akashi, Koichi
    Teshima, Takanori
    Harigae, Hideo
    Schuster, Stephen J.
    Thieblemont, Catherine
    Dreyling, Martin
    Fowler, Nathan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (02) : 251 - 259
  • [39] Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6
    Andorsky, David Jacob
    Boccia, Ralph V.
    Lash, Bradley Walter
    Vaidya, Rakhee
    Gandhi, Mitul
    Patel, Ameet
    Ibrahimi, Sami
    Madueno, Fernando Manuel Vargas
    Lee, Christina Y.
    Naik, Seema
    Haydu, J. Erika
    Fesler, Mark
    Osei-Bonsu, Kojo
    Conte, Kristin
    Doerr, Thomas
    Bai, Yang
    Sacchi, Mariana
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Li, Yanyan
    Zhang, Mengqi
    Lu, Feinan
    Song, Yuqin
    Zhu, Jun
    BLOOD, 2023, 142
12345